These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 32687065)
1. PDIA3 correlates with clinical malignant features and immune signature in human gliomas. Zhang H; Zhou Y; Cheng Q; Dai Z; Wang Z; Liu F; Fan F; Cui B; Cao H Aging (Albany NY); 2020 Aug; 12(15):15392-15413. PubMed ID: 32687065 [TBL] [Abstract][Full Text] [Related]
2. B2M overexpression correlates with malignancy and immune signatures in human gliomas. Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560 [TBL] [Abstract][Full Text] [Related]
3. P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas. Zou H; Wen C; Peng Z; Shao YΥ; Hu L; Li S; Li C; Zhou HH Oncol Rep; 2018 Feb; 39(2):501-510. PubMed ID: 29207176 [TBL] [Abstract][Full Text] [Related]
4. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. Guan X; Zhang C; Zhao J; Sun G; Song Q; Jia W EBioMedicine; 2018 Sep; 35():233-243. PubMed ID: 30131308 [TBL] [Abstract][Full Text] [Related]
5. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas. Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q Front Immunol; 2021; 12():628966. PubMed ID: 33664747 [TBL] [Abstract][Full Text] [Related]
6. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively. Tu Z; Ouyang Q; Long X; Wu L; Li J; Zhu X; Huang K Front Immunol; 2022; 13():837512. PubMed ID: 35401558 [TBL] [Abstract][Full Text] [Related]
7. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology. Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680 [TBL] [Abstract][Full Text] [Related]
8. Protein disulphide isomerase can predict the clinical prognostic value and contribute to malignant progression in gliomas. Hu Q; Huang K; Tao C; Zhu X J Cell Mol Med; 2020 May; 24(10):5888-5900. PubMed ID: 32301283 [TBL] [Abstract][Full Text] [Related]
9. Prognostic prediction and immune checkpoint profiling in glioma patients through neddylation-associated features. Qi J; Li L; Gao B; Dai K; Shen K; Wu X; Li H; Yu Z; Wang Z; Wang Z Gene; 2024 Dec; 930():148835. PubMed ID: 39127414 [TBL] [Abstract][Full Text] [Related]
10. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas. Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444 [TBL] [Abstract][Full Text] [Related]
11. Glioma hexokinase 3 positively correlates with malignancy and macrophage infiltration. Liang T; Zhou X; Wang Y; Ma W Metab Brain Dis; 2024 Jun; 39(5):719-729. PubMed ID: 38687460 [TBL] [Abstract][Full Text] [Related]
12. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas. Nakashima S; Sugita Y; Miyoshi H; Arakawa F; Muta H; Ishibashi Y; Niino D; Ohshima K; Terasaki M; Nakamura Y; Morioka M J Neurooncol; 2016 Mar; 127(1):23-32. PubMed ID: 26645886 [TBL] [Abstract][Full Text] [Related]
13. CLEC7A regulates M2 macrophages to suppress the immune microenvironment and implies poorer prognosis of glioma. Wang J; Li X; Wang K; Li K; Gao Y; Xu J; Peng R; Zhang X; Zhang S; Zhou Y; Xu S; Zhang J Front Immunol; 2024; 15():1361351. PubMed ID: 38846954 [TBL] [Abstract][Full Text] [Related]
14. Integrated bioinformatics analysis and experimental validation reveal the relationship between ALOX5AP and the prognosis and immune microenvironment in glioma. Song P; Deng H; Liu Y; Zhang M BMC Med Genomics; 2024 Aug; 17(1):218. PubMed ID: 39169376 [TBL] [Abstract][Full Text] [Related]
15. Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma. Wang ZL; Wang Z; Li GZ; Wang QW; Bao ZS; Zhang CB; Jiang T Front Immunol; 2019; 10():1756. PubMed ID: 31428092 [No Abstract] [Full Text] [Related]
16. Multifaceted bioinformatic analysis of m6A-related ferroptosis and its link with gene signatures and tumour-infiltrating immune cells in gliomas. Yang Y; Hao L; Guiyang L; Haozhe P J Cell Mol Med; 2024 Sep; 28(17):e70060. PubMed ID: 39248438 [TBL] [Abstract][Full Text] [Related]
17. PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation. Chiavari M; Ciotti GMP; Canonico F; Altieri F; Lacal PM; Graziani G; Navarra P; Lisi L Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153019 [TBL] [Abstract][Full Text] [Related]
18. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977 [TBL] [Abstract][Full Text] [Related]
19. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617 [TBL] [Abstract][Full Text] [Related]
20. IGSF8 is a potential target for the treatment of gliomas. Ren J; Huang P; Wang F Asian J Surg; 2024 Sep; 47(9):3883-3891. PubMed ID: 38453613 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]